NASDAQ
Ascendis Pharma is rated a cautious buy amid acquisition speculation, robust revenue growth, and a pivotal FDA decision on TransCon CNP. Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nea...
HOUSTON--(BUSINESS WIRE)--CenterPoint Energy, Inc.'s (NYSE: CNP) Board of Directors today declared a regular quarterly cash dividend of $0.2300 per share on the issued and outstanding shares of Common...
CenterPoint (CNP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...
Ariel Investments LLC trimmed its position in shares of CenterPoint Energy, Inc. (NYSE: CNP) by 46.6% during the second quarter, according to its most recent filing with the Securities and Exchange Co...
Palantir Technologies (PLTR), Nvidia (NVDA) and CenterPoint Energy (CNP) are joining forces on a new AI-driven platform called Chain Reaction, aiming to streaml...
Palantir expands collaboration with Northslope, first and fastest-growing Palantir-native applied AI company....
Palantir Technologies (PLTR) stock climbed about 1% on Thursday morning after revealing a collaboration with Nvidia (NVDA) and CenterPoint Energy (CNP) to enhan...
Palantir introduces Chain Reaction, an AI operating system to boost US infrastructure. Founding partners include CenterPoint, Nvidia....
Palantir Technologies , Nvidia and U.S. utility CenterPoint Energy on Thursday said they are developing a new software platform to accelerate the building of new artificial intelligence data centers....
CenterPoint Energy targets 11% rate base and 7%-9% EPS growth through 2030, underpinned by a $65 billion 10-year capital plan. Robust demand growth in Texas, especially from data centers and industria...
No price data available for this timeframe.